<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04788745</url>
  </required_header>
  <id_info>
    <org_study_id>MetFlex</org_study_id>
    <nct_id>NCT04788745</nct_id>
  </id_info>
  <brief_title>Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>MetFlex</acronym>
  <official_title>Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FightMND</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Julius Clinical, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Queensland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MetFlex is an investigator led, open-label, single-arm, Phase 2a trial to determine the&#xD;
      safety and tolerability of trimetazidine for the treatment of amyotrophic lateral&#xD;
      sclerosis/motor neuron disease (ALS/MND).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a 4-week lead-in period to obtain a stable baseline measurement of&#xD;
      clinical markers of disease and oxidative stress. After the lead-in phase, participants will&#xD;
      receive trimetazidine for 12 weeks. Participants will visit the clinic at 6-week intervals,&#xD;
      during which we will obtain a blood sample to measure the pharmacodynamic response. We will&#xD;
      also collect information regarding the rate of disease progression (i.e. ALSFRS-R and SVC).&#xD;
      At weeks 3 and 9 of treatment, participants will conduct a teleconference visit, during which&#xD;
      we will collect data on ALSFRS-R. Adverse events will be collected and recorded throughout&#xD;
      the entire trial duration. At the end of the on-treatment period, a close-out visit will&#xD;
      occur after four weeks. The total study period per participant will be 20 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, single-arm study without placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events; Safety and Tolerability</measure>
    <time_frame>16 weeks</time_frame>
    <description>The occurrence of adverse events, as assessed by Common Terminology Criteria for AEs Version 5, during the 12-week on-treatment period and 4-week wash-out period (16 weeks total).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of expression of oxidative stress markers in the plasma and/or serum of trial participants</measure>
    <time_frame>16 weeks</time_frame>
    <description>Expression of oxidative stress markers (malondialdehyde, 8-hydroxy-2'-deoxyguanosine, interleukin-6; assessed by liquid chromatography-mass spectrometry/mass-spectrometry or multiplexing) in the plasma and/or serum of trial participants throughout the treatment period (12-week) and at the end of the wash-out period (4 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of expression of oxidative stress markers in the plasma and/or serum of trial participants to inform future clinical trials in ALS/MND</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessment of the expression of oxidative stress markers (malondialdehyde, 8-hydroxy-2'-deoxyguanosine, interleukin-6; assessed by liquid chromatography-mass spectrometry/mass-spectrometry or multiplexing) in the plasma and/or serum of trial participants throughout the treatment period (12-week) and at the end of the wash-out period (4 weeks) to determine suitability for incorporation into future trial design</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Motor Neuron Disease</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimetazidine 35mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine Dihydrochloride</intervention_name>
    <description>Oral tablet, twice-daily</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 75 years&#xD;
&#xD;
          -  Signed informed consent prior to the initiation of any study-specific procedures&#xD;
&#xD;
          -  Familial or sporadic ALS/MND, defined as clinically possible, probable, or definite as&#xD;
             per the El Escorial criteria&#xD;
&#xD;
          -  Relative TRICALS risk score between -6.0 to -2.0 (75% of patients with ALS/MND)&#xD;
&#xD;
          -  Metabolic index ≥110%, at the screening visit.&#xD;
&#xD;
          -  The use of riluzole will be permitted during the study. Individuals taking riluzole&#xD;
             must be on a stable dose for at least 30 days prior to the baseline visit, or stopped&#xD;
             taking riluzole at least 30 days prior to the baseline visit.&#xD;
&#xD;
          -  Ability to swallow tablets&#xD;
&#xD;
          -  Able to lie with torso elevated at a 35° angle for 30 minutes without respiratory&#xD;
             support&#xD;
&#xD;
          -  Able to give informed consent (as judged by the investigator) and able to comply with&#xD;
             all study visits and all study procedures&#xD;
&#xD;
          -  Females must not be able to become pregnant (e.g. post-menopausal, surgically sterile&#xD;
             or using highly effective birth control methods) for the duration of the study. Highly&#xD;
             effective methods of birth control are those with a failure rate of &lt; 1% per year when&#xD;
             employed consistently and correctly, e.g. Combined (oestrogen and progestogen&#xD;
             containing) hormonal contraception associated with inhibition of ovulation:&#xD;
&#xD;
               -  oral&#xD;
&#xD;
               -  intravaginal&#xD;
&#xD;
               -  transdermal&#xD;
&#xD;
               -  Progestogen-only hormonal contraception associated with inhibition of ovulation:&#xD;
&#xD;
               -  oral&#xD;
&#xD;
               -  injectable&#xD;
&#xD;
               -  implantable&#xD;
&#xD;
               -  intrauterine device (IUD)&#xD;
&#xD;
               -  intrauterine hormone-releasing system ( IUS)&#xD;
&#xD;
               -  vasectomised partner&#xD;
&#xD;
          -  Females of child-bearing potential must have a negative serum pregnancy test at&#xD;
             screening and baseline and be non-lactating&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  History of, or current diagnosis of diabetes or medical condition that impacts whole&#xD;
             body energy expenditure (e.g. Hashimoto's, heart disease)&#xD;
&#xD;
          -  Parkinson's disease or parkinsonism, tremor, restless-leg syndrome&#xD;
&#xD;
          -  Safety Laboratory Criteria at screening related to significant kidney disease:&#xD;
&#xD;
               -  Creatinine clearance &lt; 50 mL / min (Cockcroft-Gault) based on Cystatin C&#xD;
&#xD;
          -  Tracheostomy or non-invasive ventilation (NIV) use &gt; 22 hours per day&#xD;
&#xD;
          -  Inability to swallow tablets&#xD;
&#xD;
          -  Contraindication therapy:&#xD;
&#xD;
               -  Allergy for one of the product's active pharmaceutical ingredients (APIs) or&#xD;
                  excipients.&#xD;
&#xD;
               -  Antihypertensive treatment [Trimetazidine may cause hypotension]&#xD;
&#xD;
          -  Evidence of malignant disease&#xD;
&#xD;
          -  Significant neuromuscular disease other than ALS/MND&#xD;
&#xD;
          -  Ongoing disease that may cause neuropathy&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Females actively seeking to become pregnant who are not using an adequate form of&#xD;
             contraceptive as detailed in the Inclusion criteria.&#xD;
&#xD;
          -  Deprivation of freedom by administrative or court order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyuan Ngo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Queensland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Henderson, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brisbane &amp; Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard van den Berg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ammar Al-Chalabi, MB ChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederik Steyn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Queensland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruben van Eijk, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shyuan Ngo, PhD</last_name>
    <phone>+61734431133</phone>
    <email>s.ngo@uq.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Schmidt, BNurse</last_name>
    <email>a.schmidt@uq.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Henderson, MBBS, PhD</last_name>
      <phone>+617 3646 3111</phone>
      <email>Robert.Henderson@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonard van den Berg, MD, PhD</last_name>
      <phone>+31 88 75 554 94</phone>
      <email>lberg@umcutrecht.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ammar Al-Chalabi, MB ChB, PhD</last_name>
      <phone>+44 20 7848 5192</phone>
      <email>ammar.al-chalabi@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimetazidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

